Login
$ADCT
$1.25 +$0.00 (0.0%) After hours

$ADCT SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 FORM S-3
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026

04 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

ZYNLONTA data to be featured across 5 oral presentations and multiple posters

03 Nov 2026 FORM S-4
29 Oct 2026 SCHEDULE 13G
13 Oct 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2026, by and between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Canton of Vaud, Switzerland, and organized under the laws of Switzerland ...

14 Aug 2026 SCHEDULE 13G
13 Aug 2026 FORM S-8
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

27 Jul 2026 SCHEDULE 13G
02 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 30, 2026, the Board of Directors of ADC Therapeutics SA (the “Company”), with the advice of its independent compensation consultant, approved one-time retention awards (“Awards”) to certain of the Company’s employees, including i...

02 Jul 2026 Form 4: Zaki Mohamed, Chief Medical Officer

Received 213,900 shares as a grant or award

02 Jul 2026 Form 4: Graham Peter J, Chief Legal Officer

Received 221,100 shares as a grant or award

02 Jul 2026 Form 4: Carmona Jose, Chief Financial Officer

Received 203,700 shares as a grant or award

02 Jul 2026 Form 4: Mallik Ameet, Director

Received 675,000 shares as a grant or award

24 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Planned 17% workforce reduction expected to generate annualized estimated savings of approximately $10m, enhancing financial flexibility

03 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing con...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support